Antibiotic-Induced Agranulocytosis: A Monocentric Study of 21 Cases

Andrès, Emmanuel; Maloisel, Frédéric

doi:10.1001/archinte.161.21.2619

Cited by 22 publications

(18 citation statements)

References 5 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Sulfamethoxazole is the antibiotic most commonly associated with neutropenia. Although rare, co-trimoxazole (or sulfamethoxazole)-induced agranulocytosis has been reported with severe infection and sepsis [12].…”

Section: Discussionmentioning

confidence: 99%

Severe neutropenia in children after renal transplantation: incidence, course, and treatment with granulocyte colony-stimulating factor

et al. 2015

View full text Add to dashboard Cite

show abstract

Section: Discussionmentioning

confidence: 99%

Severe neutropenia in children after renal transplantation: incidence, course, and treatment with granulocyte colony-stimulating factor

et al. 2015

View full text Add to dashboard Cite

show abstract

“…14,15 Betalactams (48% of cases) and trimethoprim-sulfamethoxazole (43% of cases) were 2 of the most frequent causative antiinfectives associated with neutropenia. 14,15 Severe neutropenia has been reported in 5% to 15% of patients who received a prolonged treatment of beta-lactams. 16 Delayed neutropenia tends to occur during the third to fourth week of treatment.…”

Section: Anti-infectivesmentioning

confidence: 99%

Nonchemotherapy Drug-Induced Neutropenia and Agranulocytosis

Pick

Nystrom

2014

Journal of Pharmacy Practice

View full text Add to dashboard Cite

Drug-induced agranulocytosis is a severe complication that has been implicated with most classes of medications. Medications such as clozapine, trimethoprim-sulfamethoxazole and methimazole have been more commonly associated with agranulocytosis than other agents. Although the pathogenesis isn't fully elucidated, it appears to be two-fold with a direct toxicity to the myeloid cell line and immune-mediated destruction. Patients may be asymptomatic at the time neutropenia is discovered or may present with more severe complications such as sepsis. In approximately 5% of cases drug-induced agranulocytosis may be fatal. Management of drug-induced agranulocytosis includes the immediate discontinuation of the offending medication, initiation of broad-spectrum antibiotics and consideration of the use of granulocyte colony-stimulating factors in high-risk patients.

show abstract

“…Reviews of this antibiotic do not mention this side-effect, although they do describe its efficacy in long-term treatment of osteomyelitis [3][4][5]. Moreover, in a recent review of 21 cases of antibiotic-induced agranulocytosis, none of the cases reviewed were related to piperacillintazobactam therapy [14]. There is little information in the literature about the toxicity of prolonged piperacillin-tazobactam treatment for conditions such as bone-related infections, despite the fact that piperacillin-tazobactam therapy is considered one of the choices for treatment of osteomyelitis [1] and diabetic foot infection [15,16].…”

mentioning

confidence: 99%

“…This may reflect the higher proportion of Pseudomonas species and polymicrobial infections found among these patients. Aztreonam, a b-lactam antibiotic that has a structural relationship with piperacillin, may theoretically facilitate neutropenia, although this is unlikely given that this toxicity is absent when aztreonam is administered alone [14,22]. A contribution from teicoplanin, quinolones, or aminoglycosides to the development of neutropenia is also quite improbable [14,23,24].…”

mentioning

confidence: 99%

Incidence of Neutropenia during Treatment of Bone-Related Infections with Piperacillin-Tazobactam

Peralta

Sánchez

Roiz

et al. 2003

Clinical Infectious Diseases

View full text Add to dashboard Cite

Of 41 patients with bone-related infections who were treated for > or =10 days with piperacillin-tazobactam, 14 (34%) developed neutropenia. Cumulative doses of piperacillin administered to neutropenic patients were higher than those administered to nonneutropenic ones (330 vs. 237 g; P=.008), and an inverse correlation was detected between the absolute neutrophil count at the end of treatment and the cumulative dose of piperacillin (r=-0.47, P=.002). Moreover, the incidence of piperacillin-tazobactam-induced neutropenia increased with an increase in the cumulative dose of piperacillin: 0% of patients in the first quartile of cumulative piperacillin doses, 33.3% in the second quartile, 40% in the third quartile, and 66.7% in the fourth quartile.

show abstract

Antibiotic-Induced Agranulocytosis: A Monocentric Study of 21 Cases

Cited by 22 publications

References 5 publications

Severe neutropenia in children after renal transplantation: incidence, course, and treatment with granulocyte colony-stimulating factor

Severe neutropenia in children after renal transplantation: incidence, course, and treatment with granulocyte colony-stimulating factor

Nonchemotherapy Drug-Induced Neutropenia and Agranulocytosis

Incidence of Neutropenia during Treatment of Bone-Related Infections with Piperacillin-Tazobactam

Contact Info

Product

Resources

About